Advertisement
Organisation › Details
Actelion Participation GmbH
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer® through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2,400 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). *
Start | 2005-12-31 existent | |
Group | Johnson & Johnson (JnJ) (Group) | |
Industry | pharmaceutical | |
Region | Allschwil BL | |
Country | Switzerland | |
Street | 16 Gewerbestr. c/o Actelion Ltd. | |
City | 4123 Allschwil BL | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Johnson & Johnson (JnJ) (Group)
- [1] Evotec SE. (1/26/23). "Press Release: Evotec Announces Agreement with Janssen to Develop Immune-based Therapies". Hamburg....
- [2] Evotec SE. (6/14/22). "Press Release: Evotec Enters a Drug Discovery Collaboration with Janssen". Hamburg....
- [3] Nouscom AG. (5/17/22). "Press Release: Nouscom Announces Janssen Receives US FDA IND Clearance for VAC85135, an ‘Off-The-Shelf’ Cancer Immunotherapy Developed using Nouscom’s Proprietary Viral Vector Platform". Basel....
- [4] GlycoEra AG. (5/3/22). "Press Release: GlycoEra AG Appoints Ganesh V. Kaundinya as President and Chief Executive Officer". Schlieren & Boston, MA....
- [5] VectivBio Holding AG. (4/21/22). "Press Release: VectivBio Appoints Patrick Malloy as Senior Vice President, Investor Relations & Strategic Communications". Basel....
- [6] F-Star Therapeutics Ltd.. (10/20/21). "Press Release: F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics". Cambridge & Cambridge, MA....
- [7] Pureos Partners AG. (9/21/21). "Press Release: Pureos Bioventures Expands the Team by the Appointment of Venture Partners". Pfäffikon....
- [8] Argenx SE. (6/7/21). "Press Release: Argenx to Regain Global Rights to Cusatuzumab". Breda....
- [9] Nouscom AG. (12/11/20). "Press Release: Nouscom Appoints Göran Ando MD as Chairman and Richard Davis PhD as Chief Business Officer". Basel....
- [10] MorphoSys AG. (12/2/20). "Press Release: MorphoSys' Licensee Announces Approval by the European Commission for Tremfya (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA)". Planegg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top